Aigen Investment Management, LP Intellia Therapeutics, Inc. Transaction History

Aigen Investment Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$31.62 - $45.78 $555,531 - $804,308	17,569 New	17,569 $555,000
Q4 2022 Feb 10, 2023	BUY	$33.21 - $62.69 $344,819 - $650,910	10,383 New	10,383 $362,000
Q2 2022 Aug 02, 2022	SELL	$38.49 - $76.21 $355,378 - $703,646	-9,233 Closed	0 $0
Q1 2022 May 05, 2022	BUY	$58.27 - $118.99 $538,006 - $1.1 Million	9,233 New	9,233 $671,000
Q2 2021 Aug 10, 2021	SELL	$60.88 - $161.91 $310,061 - $824,607	-5,093 Closed	0 $0
Q1 2021 May 11, 2021	SELL	$46.59 - $83.68 $191,904 - $344,677	-4,119 Reduced 44.71%	5,093 $409,000
Q4 2020 Feb 12, 2021	BUY	$18.83 - $63.53 $173,461 - $585,238	9,212 New	9,212 $501,000
Q3 2020 Nov 06, 2020	SELL	$17.47 - $24.93 $1.56 Million - $2.23 Million	-89,571 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$11.14 - $22.87 $570,601 - $1.17 Million	51,221 Added 133.56%	89,571 $1.88 Million
Q1 2020 May 08, 2020	BUY	$9.44 - $15.58 $362,024 - $597,493	38,350 New	38,350 $469,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.